Drug Database · Clinicians

Dapagliflozin + Sitagliptin

Brands (1) SidapviaShow all

Combinations of oral blood glucose lowering drugs [sodium-glucose co-transporter 2 (SGLT2) + dipeptidyl peptidase 4 (DPP-4) inhibitor] PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH productVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. US FDA label

    Kidney dosing: Dapagliflozin (single-agent)
    Show full dosing details
    eGFR ≥60
    No adjustment. Chronic kidney disease (CKD), heart failure and cardiovascular indications: 10 mg once daily. Glycemic control: start 5 mg once daily.
    eGFR 30–59
    CKD, heart failure and cardiovascular indications: 10 mg once daily. Glycemic control: not recommended if eGFR <45 (likely ineffective).
    eGFR 15–29
    eGFR 25–29: may start 10 mg once daily for CKD, heart failure or cardiovascular indications. eGFR <25: do not start; patients already on it may continue 10 mg once daily (label). Not for glycemic control. Guidelines (KDIGO 2024, ADA-KDIGO 2022) support starting SGLT2 inhibitors at eGFR ≥20 (off-label for dapagliflozin at 20–24) and continuing below 20 until intolerance or kidney replacement therapy.
    eGFR <15 (not on dialysis)
    Do not start. May continue 10 mg once daily if started earlier (label: continue if eGFR falls below 25). Not for glycemic control.
    Hemodialysis (intermittent)
    Not studied; trials did not enroll patients on dialysis. Trial patients who started dialysis were not required to stop (label). Effect of hemodialysis on exposure is unknown. Guidelines advise continuing until kidney replacement therapy begins (ADA-KDIGO); not effective for glucose lowering on dialysis. Specialist input.
    Peritoneal dialysis
    Not studied (label). Insufficient data: specialist input.
    CRRT
    No data in label. Insufficient data: specialist input; usually held in acute illness.
    • Dialyzable? Unknown: removal by hemodialysis has not been studied (label).
    • Monitoring Assess kidney function and volume status before starting; correct volume depletion. Expect an early small eGFR dip. Withhold at least 3 days before surgery or prolonged fasting (label); watch for ketoacidosis.

    From the Dapagliflozin monograph (renalcarematters.com, reviewed).

  • Use: JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. US FDA label

    Kidney dosing: Sitagliptin (single-agent)
    Show full dosing details
    eGFR ≥60
    100 mg once daily; no adjustment (label: eGFR ≥45).
    eGFR 30–59
    eGFR 45–59: 100 mg once daily. eGFR 30–44: 50 mg once daily (label).
    eGFR 15–29
    25 mg once daily (label).
    eGFR <15 (not on dialysis)
    25 mg once daily (label).
    Hemodialysis (intermittent)
    25 mg once daily, without regard to dialysis timing (label).
    Peritoneal dialysis
    25 mg once daily (label).
    CRRT
    No data in label.
    • Dialyzable? Modestly: about 13.5% removed over a 3–4 hour hemodialysis session (label).
    • Monitoring Assess kidney function before starting and periodically (label). Pancreatitis, hypoglycemia with sulfonylureas or insulin.

    From the Sitagliptin monograph (renalcarematters.com, reviewed).

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Film-coated tablet: 10 mg/100 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Dapagliflozin + Sitagliptin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Dapagliflozin + Sitagliptin
Package insert
SidapviaDapagliflozin (as propanediol monohydrate) + Sitagliptin (as phosphate monohydrate)
10 mg/100 mg Film-Coated TabletAlu/Alu blister pack x 14's (box of 28's)
RxVAT-exempt
SK Chemicals Co., Ltd.Korea
AstraZeneca Pharmaceuticals (Phils.), Inc.
DR-XY49396
May 15, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .